News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Alper Topal: The Keynote 921 study failed for CRPC
Alper Topal/researchgate.net
Mar 18, 2025, 12:35

Alper Topal: The Keynote 921 study failed for CRPC

Alper Topal, Medical Onoclogist at Gülhane Training and Research Hospital, shared a paper Daniel P. Petrylak and colleagues authored on X:

“The Keynote 921 study failed for CRPC.

mPFS was 8.6 months in the pembro arm compared to 8.3 months in the placebo arm.mOS was 19.6 months in the pembro arm compared to 19 months in the placebo arm. Grade 3≥side effects were more common in the pembro arm.”

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

Authors: Daniel P. Petrylak et al.

Alper Topal

Alper Topal Andrew J. Armstrong Andries M. Bergman cancer Charles Schloss Christian H. Poehlein Daniel P. Petrylak Eric Levesque Ernesto Korbenfeld Gero Kramer Howard Gurney Karim Fizazi Loic Mourey Margitta Retz Maria De Santis Meital Levartovsky Nobuaki Matsubara OncoDaily Oncology Pawel Zalewski Raffaele Ratta Ray Manneh Ray McDermott Russell Pachynski Rustem Gafanov Seok Soo Byun Sergio Bracarda Tilman Todenhofer Winald Gerritsen Xin Tong Li
Special Coverage
Blog
Apr 23, 2025, 10:12
Matthew Kurian: From ASCENT-04 may reshape frontline therapy for mTNBC
Blog
Apr 23, 2025, 10:07
Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer
Blog
Apr 23, 2025, 10:05
Tools to help gauge your personal breast cancer risk - Susan G. Komen
Blog
Apr 23, 2025, 08:55
Ahmed Alanazi: ADCs are now reshaping the standard of care for metastatic Breast Cancer
Blog
Apr 23, 2025, 08:43
Milagros Rosado Elia: Darcy Burbage as the recipient of the National Oncology Nursing Society's "Excellence in Social Media Impact Award" for 2025
Science
Apr 23, 2025, 08:35
Rachit Khandelwal: India’s First POC CAR-T Trial shows 100% CR in B-ALL
Blog
Apr 23, 2025, 08:26
The importance of trusting our instincts and advocating for our health - Digestive Cancers Europe
Blog
Apr 23, 2025, 08:18
FDA is taking bold steps to restore public trust - U.S. FDA
Blog
Apr 23, 2025, 08:09
Shrenik Shah Shares Journey from Cancer Survivor to Global Communicator
Blog
Apr 23, 2025, 07:49
Change Our Future Supports AACR 2025 Program for High School Students
Blog
Apr 23, 2025, 07:47
Julie Fleshman Marks 25 Years at PanCAN, Reflects on Personal and Professional Journey
Blog
Apr 23, 2025, 07:40
Tejas Patil: MET and NF2 Alterations Linked to Primary Resistance in ALK TKI Therapy